Windtree Therapeutics Inc
WINTDelisted- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000946486
Windtree Therapeutics Inc was delisted in 2026; its insiders filed their last Form 4 on Oct 9, 2024; no institution reported holding it in 13F filings for Q2 2026; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:03 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Apr 15, 2025 | – | – | Mar 31, 2022 | Mar 24, 2021 |
| Operating expenses | $26.1M | $20.6M | $41.3M | $77.3M | $30.3M |
| Research and development | $16.3M | $8.34M | $11.1M | $17.8M | $15.4M |
| Selling, general and administrative | $8.74M | $9.20M | $10.8M | $14.5M | $14.9M |
| Operating income | -$26.1M | -$20.6M | -$41.3M | -$77.3M | -$30.3M |
| Interest expense | – | $50.0K | $53.0K | $114.0K | $125.0K |
| Income tax | -$6.00K | $0 | -$1.37M | -$9.99M | – |
| Net income | -$1.79M | -$20.3M | -$39.2M | -$67.6M | -$32.6M |
| EPS, basic | $-104.35 | $-5.24 | $-62.23 | – | – |
| Weighted shares, basic | 52.6M | 3.88M | 630.0K | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024! | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Apr 15, 2025 | – | – | Mar 31, 2022 | Mar 24, 2021 |
| Cash and equivalents | $1.78M | $4.32M | $6.17M | $22.3M | $16.9M |
| Total current assets | $2.57M | $5.38M | $7.38M | $23.5M | $18.1M |
| Property, plant and equipment | $111.0K | $183.0K | $262.0K | $1.01M | $924.0K |
| Goodwill | – | $0 | $3.06M | $15.7M | $15.7M |
| Intangible assets | – | – | $9.70M | $17.0M | $77.1M |
| Total assets | $27.9M | $32.4M | $38.0M | $74.8M | $112.9M |
| Accounts payable | $1.88M | $809.0K | $249.0K | $693.0K | $1.16M |
| Total current liabilities | $5.72M | $4.00M | $2.46M | $4.92M | $6.13M |
| Total liabilities | $14.7M | $29.0M | $27.9M | $32.9M | $43.3M |
| Shareholders' equity | $10.0M | $3.39M | $10.0M | $41.9M | $69.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Apr 15, 2025 | – | – | Mar 31, 2022 | Mar 24, 2021 |
| Operating cash flow | -$15.4M | -$13.4M | -$19.5M | -$23.7M | -$25.3M |
| Capital expenditures | $12.0K | $15.0K | $13.0K | $279.0K | $291.0K |
| Free cash flow | -$15.4M | -$13.5M | -$19.5M | -$23.9M | -$25.6M |
| Stock-based compensation | $455.0K | $1.28M | $3.09M | $7.24M | $5.68M |
| Dividends paid | $657.0K | – | – | – | – |
| Investing cash flow | -$12.0K | -$15.0K | $197.0K | -$279.0K | -$291.0K |
| Financing cash flow | $12.7M | $11.6M | $3.08M | $29.4M | $20.0M |
| Net change in cash | -$2.68M | -$1.86M | -$16.2M | $5.42M | -$5.65M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 14, 2025 | 33.7M | +275.0% | SEC |
| Aug 19, 2025 | 29.3M | +4,855.9% | SEC |
| May 15, 2025 | 3.66M | +518.6% | SEC |
| Apr 15, 2025 | 3.56M | −61.3% | SEC |
| Nov 22, 2024 | 8.99M | +74.6% | SEC |
| Aug 19, 2024 | 591.9K | −88.5% | SEC |
| May 15, 2024 | 591.9K | −88.5% | SEC |
| Apr 1, 2024 | 9.18M | +910.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.